Related Experiment Videos
FiSBoG (fetal steroid binding glycoprotein) as a fetal function test
1St. James's University Hospital, Leeds, England.
Steroids
|October 1, 1988
Summary
Fetal protein S-B (FiSBoG) in maternal serum shows no significant role in assessing fetal well-being during late pregnancy. This study compared levels in normal versus abnormal pregnancies, finding no reliable predictive value.
Area of Science:
- Biochemistry
- Maternal-Fetal Medicine
- Clinical Diagnostics
Background:
- A novel fetal protein, Fetal protein S-B (FiSBoG), is detectable in cord blood and maternal serum during late pregnancy.
- Its potential utility as a biomarker for fetal well-being requires investigation.
Purpose of the Study:
- To evaluate the potential of Fetal protein S-B (FiSBoG) in maternal serum as a test for fetal well-being.
- To compare FiSBoG levels between normal and various abnormal pregnancy cohorts.
Main Methods:
- Maternal serum samples from 31 normal pregnancies were analyzed.
- FiSBoG levels were compared with those from 23 pregnancies complicated by twins, stillbirth, pre-eclampsia, antepartum hemorrhage, or small-for-dates infants.
Main Results:
- Fetal protein S-B (FiSBoG) levels in maternal serum did not show significant differences or trends that could reliably distinguish between normal and abnormal pregnancies.
- No significant correlation was found between FiSBoG levels and adverse pregnancy outcomes.
Conclusions:
- Fetal protein S-B (FiSBoG) does not appear to be a useful biomarker for assessing fetal well-being in late pregnancy.
- Further research is needed to explore other potential roles or markers for fetal health monitoring.